Tech Company Financing Transactions
VST BIO Funding Round
VST BIO secured a funding round on 3/17/2026. Investors included Coefficient Capital and private investors.
Transaction Overview
Company Name
Announced On
3/17/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Coefficient Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead program into first-in-human studies in 2026, expand its platform, and build core development capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA Undisclosed
USA
San Diego, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
VST BIO is a biotechnology company that develops antibodies for the treatment of inflammatory and cardiovascular diseases, including stroke and acute myocardial infarction, as well as sepsis. VST Bio utilizes this new class of therapeutics to control injury-induced inflammation and vascular permeability (and control edema formation) in acute stroke, and other acute cardiovascular disease, dramatically expanding the opportunities for effective medical therapy in stroke patients, in particular for the majority of patients who do not present within the first hours after onset of symptoms, and cannot be treated with conventional standard-of-care medical therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Krisztina Zsebo
Browse more venture capital transactions:
Prev: 3/17/2026: Imperative Care venture capital transaction
Next: 3/17/2026: Blify venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs